REFERENCES
- van den Berg ME, Castellote JM, Mahillo-Fernandez I, de Pedro-Cuesta J. Incidence of spinal cord injury worldwide: a systematic review. Neuroepidemiology. 2010;34(3):184–192.
- National Spinal Cord Injury Statistical Center Spinal Cord Injury Facts and Figures at a Glance Birmingham (AL) National SCI Statistical Center [Internet]; 2013. Available from: https://www.nscisc.uab.edu/PublicDocuments/fact_figures_docs/Facts%202013.pdf Accessed June 4, 2013.
- Sekhon LH, Fehlings MG. Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine (Phila Pa 1976). 2001;26(24 Suppl):S2–S12.
- Bracken MB, Shepard MJ, Holford TR, et al. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial. J Neurosurg. 1998;89(5):699–706.
- Eck JC, Nachtigall D, Humphreys SC, Hodges SD. Questionnaire survey of spine surgeonson the use of methylprednisolone for acute spinal cord injury. Spine (Phila Pa 1976). 2006;31(9):E250–E253.
- Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43(11):707–724.
- Hanon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure. 2001;10(4):287–293.
- Oliveira AA, Almeida JP, Freitas RM, et al. Effects of levetiracetam in lipid peroxidation level, nitrite-nitrate formation and antioxidant enzymatic activity in mice brain after pilocarpine-induced seizures. Cell Mol Neurobiol. 2007;27(3):395–406.
- Nursoy E, Ogden M, Bakar B, Çagdaş G, et al. Research on the effects of levetiracetam in spinal cord injury model in rats: a experimental study. J Investig Surg. 2020;33(3):252–262.